Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2024-01-02 Share Issue/Capital Cha…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Amended Appendix 3Gs for Unquoted Warrants 38 pages 737.4KB
Share Issue/Capital Change Classification · 95% confidence The document is an Appendix 3G form filed with the ASX, titled 'Notification of issue, conversion or payment up of unquoted equity securities.' It details the issuance and adjustments related to unquoted securities, including changes to American Depositary Receipt (ADR) ratios and warrants. The form is regulatory in nature, notifying the market of securities issuance and amendments, rather than presenting financial results, management commentary, or governance information. It is not an annual or interim report, earnings release, or management discussion. It is a specific regulatory announcement about securities issuance and conversion, fitting the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is the actual notification, not just an announcement of a report publication or a certification. Therefore, the correct classification is SHA with high confidence.
2024-01-02 English
Appendix 3Y for Joseph Swedish 2 pages 239.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about a director's change in shareholdings, including the number of securities held before and after the change, the nature of the interest, and transaction details. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director share transactions. The content is specific to a director's personal share transactions and not a broader financial report or announcement. Therefore, this fits the definition of 'Director's Dealing' filings.
2024-01-02 English
Notification of cessation of securities - MSB 4 pages 23.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of incentive rights (options) for Mesoblast Limited. It provides specifics on the securities that have ceased, the reason for cessation (expiry without exercise or conversion), and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or detailed financial data. It is not a full report but an official notification related to capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is 3620 characters, which is consistent with an announcement rather than a full report.
2023-12-27 English
Appendix 2A 20 pages 492.7KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the securities being quoted, dates of issue, and references to previous announcements such as Appendix 3B. This type of document is a regulatory filing related to capital markets and securities issuance, specifically an application for quotation of new or previously announced securities. It is not a financial report, earnings release, management discussion, or any other report type. It is also not a short announcement but a formal regulatory form required by the exchange for listing securities. Therefore, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-12-27 English
Appendix 3Ys- J Swedish,B Burns,J Bell,P Krause,P Facchina 12 pages 428.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including acquisitions and disposals of shares and options. The content is focused on personal share transactions by directors, including dates, number of securities, and nature of transactions. There is no financial performance data, earnings information, or management discussion. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains detailed transaction data, confirming it is not a mere announcement or certification. Therefore, the correct classification is Director's Dealing (DIRS).
2023-12-27 English
Update on Institutional Placement and Entitlement Offer 2 pages 147.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement providing an update on an institutional placement and entitlement offer by Mesoblast Limited, including details on the amount raised, share allotment dates, and exercise price adjustments for options and warrants. It does not contain financial statements or detailed financial analysis but rather focuses on fundraising activities and capital structure changes. The document length is 7,723 characters, which is sufficient to contain substantive information, but the content is clearly about capital raising and share issuance. There is no indication that this is a full financial report, earnings release, or regulatory filing beyond the capital update. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2023-12-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.